Raymond James Financial
ADPT icon

Raymond James Financial’s Adaptive Biotechnologies ADPT Stock Holding History

Raymond James Financial’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.68M Buy
404,712
+22,417
+6% +$343K ﹤0.01% 2279
2026
Q1 		$5.31M Buy
382,295
+55,000
+17% +$876K ﹤0.01% 2542
2025
Q4 		$5.32M Buy
327,295
+45,744
+16% +$747K ﹤0.01% 2463
2025
Q3 		$4.21M Buy
281,551
+13,398
+5% +$163K ﹤0.01% 2585
2025
Q2 		$3.12M Buy
268,153
+173,620
+184% +$1.58M ﹤0.01% 2725
2025
Q1 		$702K Buy
+94,533
New +$727K ﹤0.01% 3727

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Raymond James Financial's ADPT Position: Q2 2026 in Review

Raymond James Financial increased its Adaptive Biotechnologies (ADPT) stake by 5.9% in Q2 2026, buying an estimated $343K and bringing the position to 404,712 shares worth $8.68M. The position accounts for ﹤0.01% of the portfolio, ranked #2279.

Raymond James Financial first reported a position in ADPT in Q1 2025 and has held it in 6 quarters since. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Raymond James Financial held 404,712 shares of Adaptive Biotechnologies worth $8.68M as of Q2 2026.
  • Raymond James Financial bought 22,417 Adaptive Biotechnologies shares in Q2 2026, an estimated $343K.
  • Adaptive Biotechnologies made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #2279 holding.
  • Raymond James Financial first reported a position in Adaptive Biotechnologies in Q1 2025 and has held it in 6 quarters since.
  • 300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.